NMN vs NR: NAD+ Precursors in the Research

The gist

NMN vs NR is the supplement world's favorite argument, and it is really a question about two NAD+ precursors — two building blocks the body converts into NAD+ (the energy-handling coenzyme every cell uses). NMN (nicotinamide mononucleotide) sits one step from NAD+. NR (nicotinamide riboside) is a step further back, converted to NMN first. Both raise the NAD+ in your blood in human trials. When researchers finally compared them at the same molar dose, NR raised blood NAD+ more — and it is also the precursor with the longer clinical track record. Neither has been shown to extend human lifespan; that part is still unstudied.

The 2026 equimolar crossover: NR raised blood NAD+ 2.3x more than NMN

The cleanest recent comparison is a 2026 Phase I pharmacokinetic crossover trial that gave the same people both precursors at the same dose. At 1200 mg/day for eight days, NR raised blood NAD+ by 161%, while NMN at the identical dose raised it by 67% — a 2.3-fold advantage for NR at equimolar dose ^[13]. NR also significantly increased brain NAD+, and the crossover design (each participant serving as their own control) removed the individual-to-individual variation that muddies parallel-group studies. On the strength of that result, the investigators carried NR forward into the study's neurological phase ^[13].

That does not make NMN inert — far from it. It means that, milligram for milligram in this head-to-head, NR delivered more blood NAD+. The comparison is one trial; it is the best direct one to date.

Nicotinamide Riboside (NR): the Most-Studied NAD+ Booster

Of the two, NR has the deeper clinical record. The benchmark dose-finding trial raised whole-blood NAD+ by 22%, 51%, and 142% at 100, 300, and 1000 mg/day over eight weeks, with the elevation maintained throughout and no flushing, no LDL-cholesterol rise, and no disruption of one-carbon metabolism ^[4]. NR's biochemistry is well characterized down to the enzyme: it is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to NMN, a Preiss-Handler-independent route to NAD+, and the crystal structure of human NRK1 has been solved ^[7]. NR has also been tested in disease populations — a 24-week randomized trial in long-COVID patients raised NAD+ and showed within-group improvements in fatigue and sleep, though it did not beat placebo on group-level cognitive scores ^[11].

Nicotinamide Mononucleotide (NMN) in Human Trials

NMN is the more popular precursor and the one closer to NAD+ in the pathway, one step away via the enzyme NMNAT ^[8]. Its human evidence is real but narrower on hard outcomes. The most-cited functional result: 250 mg/day for 10 weeks improved muscle insulin sensitivity in prediabetic, postmenopausal women, with no change in body composition or HbA1c ^[1]. A multicenter dose-response trial (300/600/900 mg/day, 60 days) raised blood NAD+ at all doses and improved walking distance, naming 600 mg/day as optimal ^[3]. But the 2025 meta-analysis of 12 NMN trials found no significant effect on glucose or lipid markers versus placebo ^[14], and NMN carries the open FDA dispute over its supplement status ^[10]. The most-replicated NMN research dose is 250 mg/day.

How to read the comparison

Two honest takeaways. First, both precursors raise blood NAD+; that is the settled part, and it is why the human clinical trials of NAD+ precursors agree on at least that endpoint. Second, the single best direct comparison gives NR the edge on blood — and, importantly, brain — NAD+ at equal dose ^[13], and NR has the longer safety record at high doses. What neither precursor has is proof of a hard human outcome: longevity, disease prevention, or 'looking younger' have not been demonstrated for either in controlled trials ^[10]. The argument over which precursor is 'better' is, for now, an argument about a biomarker. See the full reference list for every study cited here.